PuSH - Publikationsserver des Helmholtz Zentrums München

Stemmer, K. ; Müller, T.D. ; DiMarchi, R.D.* ; Pfluger, P.T. ; Tschöp, M.H.

CNS-targeting pharmacological interventions for the metabolic syndrome.

J. Clin. Invest. 130, 4058-4071 (2019)
Verlagsversion Preprint Forschungsdaten DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Glucagon-like Peptide-1; Controlled-release Phentermine/topiramate; Dependent Insulinotropic Peptide; Cannabinoid-1 Receptor Blocker; Melanin-concentrating Hormone; Neurons Regulate Energy; Once-daily Liraglutide; Diet-induced Obesity; Food-intake; Weight-loss
ISSN (print) / ISBN 0021-9738
e-ISSN 1558-8238
Zeitschrift Journal of Clinical Investigation
Quellenangaben Band: 130, Heft: 10, Seiten: 4058-4071 Artikelnummer: , Supplement: ,
Verlag American Society of Clinical Investigation
Verlagsort 2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)